Office of Research and Development

Home

 

Departments

 

Search

 

Department · Name/Training · Academic Degrees · Contact Information · Grant Support · Publications · Previous Graduate Students · Current Research Projects · Specialized Lab/Clinical Research Resources · Back to Department List 

Internal Medicine

Stephen I. Rennard, A.B., M.D.

Back to Top

ACADEMIC DEGREES:
Medical School: Baylor College of Medicine
Residency training: Barnes Hospital/Washington University, 1975-1977
Post-doctoral training: Pulmonary Branch, National Heart Lung and Blood Institute, 1979 -1984

Back to Top

Contact Name: Stephen I. Rennard, M.D.
Phone Number: 402-559-7313
Fax Number: 402-559-4878
e-mail address: srennard@unmc.edu

Back to Top

Pharmacogenetics of nicotine addition and treatment (PNAT)

NIH (Subcontract from UCSF)

10/1/05

6/30/10

Fetal smoke exposure and emphysema:  Role of stem cells

NIH

5/2/05

3/31/08

Minority supplement to stem cells for the treatment of emphysema (Chantal Afuh)

NIH:  NHLBI

5/1/04

4/30/06

Cigarette smoke modulates stem-progenitor cell differentiation into lung fibroblasts in vivo

Philip Morris External Research Program

8/1/05

5/31/08

Stem cells for the prevention and treatment of emphysema

NIH

8/1/03

6/30/07

Teen counselors for smoking cessation (Co-investigator)

NIH

7/1/03

6/30/07

Validation of biomarkers of exposure and host response

Institute for Science & Health

12/1/04

11/31/06

Cytokine modulation of matrix remodeling

NIH

9/30/99

8/31/05

Tissue engineering using adult stem cells

NRI

7/1/00

6/30/03

A proteomics approach in the study of novel COPD markers

NIH

Subcontract with Southampton General Hospital

10/1/02

9/30/06

Preliminary data to support  Edg Receptor Signaling Modulates Fibroblast-Mediated-Repair

UNMC College of Medicine 2003 Dean’s Indirect Cost Program

10/1/03

10/31/04

Sharing Clinic smoking cessation services

Chest Foundation

8/1/03

7/31/04

Comparison of the efficacy and safety of a 20 mg/day oral dose of Rimonabant versus placebo as an aid to smoking cessation a US randomized, double-blind, 2-arm placebo controlled parallel group, fixed dose, 12 week, multicenter, phase III trial:  2-week screen, 10 week treatment 

Sanofi-Synthelabo

5/1/04

4/30/05

A randomized, double-blind, placebo-controlled, parallel group, multi-center, multiple dose (7 days) dose-ranging study, to assess the efficacy and safety of 4 doses of QAB 149 (50, 100, 200, & 400 ug) delivered via a multiple dose inhaler and 1 dose of QAB (400 ug) delivered via a single dose inhaler in patients with COPD

Novartis

9/13/04

2/28/05

Effect of Roflumilast on exacerbation rate in patients with Chronic Obstructive Pulmonary Disease.  A 52 week, multi-center, double-blind study with 500 mcg Roflumilast once daily versus placebo

Altana

4/27/04

10/31/05

Smoking cessation in COPD

GlaxoSmithKline

9/1/03

12/31/06

         

Comparison and efficacy of 2 oral doses or Rimonabant, 5 mg/day or 20 mg/day Versus placebo, as an aid in prevention of relapse of smoking-A multiple country, 

Sanofi

2/24/03

12/31/05

A phase II, multicenter, randomized, double-blind, placebo-controlled parallel group, dose finding study evaluating the safety and efficacy of infliximab administration in symptomatic subjects with moderate to severe chronic obstructive pulmonary disease (COPD)

Centocor

2/1/03

2/28/05

A randomized, multi-center, placebo-controlled, double-blind, parallel group study to evaluate the safety of treatment of 12 µg B.I.D. formoterol as evaluated by holter monitoring, in adult patients with chronic obstructive pulmonary disease  (COPD)

Novartis

11/1/02

10/30/04

A phase 2, multi-center, randomized, double-blind, placebo-controlled, parallel-arm, dose comparison study to assess immunogenicity and safety of 3'-aminomethylnicotine-P. aeruginosa r-exoprotein A  conjugate vaccine (NICVAX) administered to smokers 

Nabi

7/17/03

7/16/04

A 24 week, randomized, placebo-controlled, parallel group study comparing roflumilast  500 mcg daily vs placebo on pulmonary function and respiratory symptoms in patients with COPD

Pharmacia/Pfizer

8/31/03

1/31/05

A multicenter, randomized, double-blind, placebo controlled phase 2a dose response study of the safety and tolerability  of two doses of RO3300074 given for 4 weeks to patients with moderate to severe symptomatic emphysema

Roche

8/31/03

8/30/04

A twelve week double-blind, placebo-controlled, randomized, multicenter study with follow-up evaluating the safety and efficacy of varenicline tartrate(CP525,555) in comparison to zyban in smoking cessation

Pfizer

8/1/03

4/30/05

Evaluation of the interactions between beta agonists and glucocorticoids on the release and activation of matrix metalloproteases produced by fibroblasts in three dimensional collagen gel culture

AstraZeneca LP

1/1/03

12/31/04

Regulation by MCP-1 of the interactions between monocytes and fibroblasts

Centocor

11/1/03

10/31/06

Evaluation of cilomilast-salmeterol interactions in modulating fibroblast recruitment and matrix reorganization

GlaxoSmithKline

10/1/03

3/31/04

Comparison of the efficacy and safety of 2 oral doses of rimonabant, 5 mg/day or 20 mg/day, versus placebo, as an aid to smoking cessation—a single country, randomized, double-blind, 3 arm, placebo-controlled, parallel-group, fixed dose, 52-week, multi-center, phase 3 trial; 2-week screen, 10-week treatment, 40-week follow-up

Sanofi-Synthelabo

9/1/02

2/28/04

A multicenter, randomized, double-blind, parallel group, placebo-controlled study to investigate the long-term effect of salmeterol/fluticasone propionate (Seretide/Viani/Advair) 50/500 micrograms BID salmeterol 50 micrograms and fluticasone propionate 500 micrograms BID, all delivery via the diskus/accuhaler inhaler

GlaxoSmithKline

6/8/01

5/31/05

A 12-month double blind, randomized, parallel group, multicenter efficacy and safety study of symbicort pMDI 2x 160/4.5 ug bid compared to placebo in patients with COPD

AstraZeneca

9/1/05

12/30/07

Role of EP3 receptor signaling in modulation of fibroblast repair

Astellas USA Foundation

11/1/05

10/31/06

Influence of the novel, selective PDE4 inhibitor roflumilast on selected functions of human lung fibroblasts in vitro

Altana

7/1/04

6/30/07

Role of cholinergic signaling in modulating fibroblast-mediated repair

Boehringer-Ingelheim

10/1/05

9/30/06

Exhaled breath condensate collaboration

Lorillard

10/1/05

9/3/07

Evaluation of airway gene expression in COPD and controlled populations

Wyeth

12/23/05

12/22/07

Smoking and smoking cessation as RA disease modifier

NE DHHS

7/1/03

12/31/04

A multi-center study to determine the exposure of adult US smokers

Covance

4/2/03

3/31/04

A 24-week, randomized, placebo-controlled parallel group study

Pharmacia and Upjohn

7/8/03

7/7/04

Back to Top

ORIGINAL PUBLICATIONS
Liu XD, Conner H, Kobayashi T, Kim HJ, Wen FQ, Abe S, Fang QH, Wang XQ,  Hashimoto M, Bitterman P, Rennard SI. Cigarette smoke extract induces DNA damage but not apoptosis in human bronchial epithelial cells.  Am J Respir Cell Molec Biol, 2005; 33:121-129.

Hatsukami DK, Rennard S, Jorenby D, Fiore M, Koopmeiners J, de Vos A, Horwith G, Pentel PR. Safety and immunogenicity of a nicotine conjugate vaccine in current smokers. Clin Pharmacol Therapeutics 2005; 78:456-467.

Freeman TL, Haver A, Duryee MJ, Tuma DJ, Klassen LW, Hamel FG, White RL, Rennard SI, Thiele GM.  Aldehydes incigarette smoke react with the lipid peroxidation product malonaldehyde to form fluorescent protein adducts on lysines, Chem Res Toxicol, 2005; 18:817-824.

Kato J, Kohyama T, Okazaki H, Desaki M, Nagase T, Rennard SI, Takizawa H.  Leukotriene D(4) potentiates fibronectin-induced migration of human lung fibroblasts.  Clin Immunol 2005; 117:177-181.

Rennard SI.  Understanding inflammation in obstructive lung disease.  J COPD 2005; 6:4-10.

Barr RG, Celli BR, Martinez FJ, Ries A, Rennard S, Reilly J, Sciurba FC, Thomashow B, Wise RA for the COPD Resource Network.  Physician and patient perceptions in COPD:  Results of the COPD Resource Network Needs Assessment Survey.  Am J Med 2005; 118:1415.e9-1415.e17.

Celli BR, Calverley PMA, Rennard SI, Wouters EFM, Agusti A, Anthonisen N, MacNee W, Jones P, Pride N, Rodriguez-Roisin R, Rossi A, Wanner A.  Proposal for a multidimensional staging system for chronic obstructive pulmonary disease.  Respir Med 2005; 99:1546-1554.

Kobayashi T, Liu X, Wen FQ, Fang Q, Abe S, Wang XQ, Hashimoto M, Shen L, Kawasaki S, Kim HJ, Kohyama T, Rennard SI. Smad3 mediates TGF-b1 induction of VEGF production in lung fibroblasts.  Biochem Biophys Res Commun 2005; 327:393-398.

Hatsukami DK, Rennard S, Patel MK, Kotlyar M, Malcolm R, Nides MA, Dozier G, Bars MP, Jamerson BD. Effects of sustained-release bupropion among persons interested in reducing by not quitting smoking.  Am J Med 2004; 116:151-157.

Kim H, Liu X, Kohyama T, Kobayashi T, Conner H, Abe S, Fang Q, Wen F-Q, Rennard, SI.  Cigarette smoke stimulates MMP-1 production by human lung fibroblasts through the ERK1/2 pathway.  Journal of COPD 2004; 1:13-23.

Wen FQ, Liu X, Kobayashi T, Abe S, Fang Q, Kohyama T, Ertl R, Terasaki Y, Manouilova L, Rennard SI.  IFN-g inhibits TGF- production in human airway epithelial cells by targeting Smads. Am J Respir Cell Molec Biol 2004; 30:816-822.

Kohyama T, Liu X, Wen FQ, Kobayashi T, Fang Q, Abe S, Cieslinski L, Barnette MS, Rennard SI. Cytokines modulate cilomilast response in lung fibroblasts. Clin Immunol 2004; 111:297-302.

Kim H, Liu X, Kobayashi T, Conner H, Kohyama T, Wen FQ, Fang Q, Abe S, Bitterman P, Rennard SI.  Reversible cigarette smoke extract-induced DNA damage in human lung fibroblasts.  Am J Respir Cell Molec Biol 2004; 31:483-490.

Abe S, Boyer C, Liu X, Wen FQ, Kobayashi T, Fang Q, Wang X, Hashimoto M, Sharp JG, Rennard SI.  Cells derived from the circulation contribute to the repair of lung injury. Am J Respir Crit Care Med 2004; 170:1158-1163.

Fang Q, Liu X, Abe S, Kobayashi T, Wang KQ, Kohyama T, Hashimoto M, Wyatt T, Rennard SI.  Thrombin induces collagen gel contraction partially through PAR1 activation and PKC-.  Eur Respir J 2004; 24:918-924.

Watson L, Vestbo J, Postma DS, Decramer M, Rennard S, Kiri VA, Vermeire PA, Soriano JB.  Gender differences in the management and experience of chronic obstructive pulmonary disease.  Respir Med 2004; 998:1207-1213.

Pauwels R, Calverley P, Buist AS, Rennard S, Fukuchi Y, Stahl E, Lofdahl CG.  COPD exacerbations:   

the importance of a standard definition.  Respir Med 2004; 98:99-107.

Kohyama T, Liu X, Wen FQ, Kobayashi T, Abe S, Rennard SI.  IL-4 and IL-13 induce chemotaxis of human foreskin fibroblasts, but not human fetal lung fibroblasts.  Inflammation 2004; 28:33-37.

Fredriksson K, Stridh H, Lundahl J, Rennard SI and Skold CM. Red blood cells inhibit proliferation and stimulate apoptosis in human lung fibroblasts in vitro. Scand J Immunol, 2004; 59:559-65.

Calverley P, Rennard S.  Application of management guidelines to the assessment of new medicines:  driving us forward or holding us back?  Eur Respir J, 2004; 23:793-794.

Ohta K, Fukuchi Y, Grouse L, Mizutani R, Rabe KF, Rennard SI, Zhong, N-S.  A Prospective clinical survey of theophylline safety in 3,810 elderly patients with asthma or COPD.  Respir Med, 2004; 98:1016-1024.

Wang H, Liu X, Umino T, Kohyama T, Zhu YK, Wen FQ, Spurzem JR, Romberger DJ, Kim HJ, Rennard SI.  Effect of cigarette smoke on fibroblast-mediated gel contraction is dependent on cell density.  Am J Phys 2003; 283:L205-L213.

Wen FQ, Liu X, Manda W, Terasaki Y, Kobayashi T, Abe S, Fang Q, Ertl R, Manouilova L, Rennard SI.  The cytokine- and TGF-b-enhanced vascular endothelial growth factor production by cultured human airway smooth muscle cells is attenuated by interferon-gamma and corticosteroids.  J Allergy Clin Immunol 2003; 111:1307-1318.

Carnevali S, Mio T, Adachi Y, Spurzem JR, Striz I, Romberger DJ, Illig M, Rennard, SI.  Gamma radiation inhibits fibroblast-mediated collagen gel retraction.  Tissue & Cell 2003; 35:459-469.

Abe S, Lauby G, Boyer C, Rennard SI, Sharp JG.  Transplanted BM and BM side population cells contribute progeny to the lung and liver in irradiated mice.  Cytotherapy 2003; 5:523-533.

Liu X, Wen FQ, Kobayashi T, Abe S, Fang Q, Piek E, Bottinger EP, Roberts AB, Rennard SI.  Smad3 mediates the TGF-b-induced contraction of type I collagen gels by mouse embryo fibroblasts.  Cell Motility and the Cytoskeleton 2003; 54:248-253.

Hughes JR, Callas PW, High Dose Study Group.  Past alcohol problems do not predict worse smoking cessation outcomes.  Drug and Alcohol Dependence 2003; 71:269-273.

Wang H, Liu X, Umino T, Kohyama T, Zhu YK, Wen FQ, Spurzem JR, Romberger DJ, Kim HJ, Rennard SI.  Effect of cigarette smoke on fibroblast-mediated gel contraction is dependent on cell density.  Am J Phys 2003; 283:L205-L213.

Wang HJ, Liu XD, Umino T, Sköld CM, Zhu YK, Kohyama T, Spurzem JR, Romberger DJ, Rennard SI.  Cigarette smoke inhibits human bronchial epithelial cell repair processes.  Am J Respir Cell Molec Biol 2002; 25:772-779.

Rennard SI, Umino T, Millatmal T, Daughton DM, Manouilova LS, Ullrich FA, Patil KD, Romberger DJ, Floreani AA, Anderson JR. Evaluation of subclinical respiratory tract inflammation in heavy smokers who switch to a cigarette-like nicotine delivery device which primarily heats tobacco.  Nicotine & Tobacco Research 2002; 4:467-476.

Fredriksson K, Lundahl J, Fernvik E, Eklund A, Liu XD, Rennard SI, Sköld CM.  Red blood cells stimulate fibroblast-mediated contraction of three dimensional collagen gels in co-culture.  Inflammation Res 2002; 51:245-251.

Kohyama T, Liu X, Wen FQ, Zhu YK, Wang HJ, Kim HJ, Takizawa H, Cieslinski LB, Barnette MS, Rennard SI.  PDE4 inhibitors attenuate fibroblast chemotaxis and contraction of native collagen gels:  Potential anti-fibrotic effect.  Am J Respir Cell Molec Biol 2002; 26:694-701.

Kohyama T, Liu, X, Kim HJ, Kobayashi T, Ertl RF, Wen FQ, Takizawa H, Rennard SI.  Prostacyclin analogs inhibit fibroblast migration.  Am J Phys 2002; 283:L428-L432

Spurzem JR, Gupta J, Veys T, Kneifl KR, Rennard SI, Wyatt TA.  Activation of protein kinase A accelerates bovine bronchial epithelial cell migration.  Am J Physiol Lung Cell Mol Physiol 2002; 282:L1108-L1116.

Kohyama T, Wyatt TA, Liu X, Wen FQ, Kobayashi T, Fang Q, Kim HJ, Rennard SI.  PGD2 modulates fibroblast-mediated  native collagen gel contraction.  Am J Respir Cell Molec Biol 2002; 27:375-381.

Kohyama T, Liu X, Wen FQ, Kobayashi T, Abe S, Ertl Rennard SI.  Nerve growth factor stimulates fibronectin-induced fibroblast migration. J Lab Clin Med 2002; 140:329-335.

Kohyama T, Liu X, Zhu YK, Wen FQ, Wang H, Fang Q, Kobayashi T, Rennard SI.  Phosphodiesterase4 inhibitor cilomilast inhibits fibroblast-mediated collagen gel degradation induced by TNF- neutrophil elastase.  Am J Respir Cell Molec Biol 2002; 27:487-494.

Rennard S, Decramer M, Calverley PM, Pride NB, Soriano JB, Vermeire PA, Vestbo J.  The impact of COPD in North America and Europe in 2000:  The patients’ perspective of the Confronting COPD International Survey.  Eur Resp J 2002; 20:799-805.

Liu X, Kohyama T, Wang H, Zhu YK, Wen FQ, Kim HJ, Romberger DJ, Rennard SI.  Th2 cytokine regulation of type I collagen gel contraction mediated by human lung mesenchymal cells.  Am J Physiology Lung Cell Mol Physiology 2002; 282:L1049-L1056.

Wen FQ, Kohyama T, Sköld CM, Zhu YK, Liu X, Romberger DJ, Stoner J, Rennard SI.  Glucocorticoids modulate TGF-ß production.  Inflammation 2002; 26:279-290.

Kohyama T, Liu X, Wen FQ, Kim HJ, Takizawa H, Rennard SI.  Potentiation of human lung fibroblast chemotaxis by the thromboxane A2 analog U-46619. J Lab Clin Med 2002; 139:43-49.

Mio T, Liu X, Toews ML, Rennard SI.  Lysophosphatidic acid augments fibroblast-mediated contraction of released collagen gels J Lab Clin Med 2002; 139:20-27.

Wen FQ, Kohyama T, Liu, X, Zhu YK, Wang H, Kim HJ, Kobayashi T, Abe S, Spurzem JR, Rennard SI.  IL-4 and IL-13 enhanced TGF-b2 production in cultured human bronchial epithelial cells is attenuated by IFN-.  Am J Respir Cell Molec Biol 2002; 26:484-490.

Kohyama T, Liu XD, Wen FQ, Kim HJ, Takizawa H, Rennard SI.  Prostaglandin D2 inhibits fibroblast migration.  Eur Resp J 2002; 19:684-689.

Kohyama T, Liu X, Wen FQ, Zhu YK, Wang HJ, Kim HJ, Takizawa H, Cieslinski LB, Barnette MS, Rennard SI.  PDE4 inhibitors attenuate fibroblast chemotaxis and contraction of native collagen gels:  Potential anti-fibrotic effect.  Am J Respir Cell Molec Biol 2002; 26:694-701.

Spurzem JR, Gupta J, Veys T, Kneifl KR, Rennard SI, Wyatt TA.  Activation of protein kinase A accelerates bovine bronchial epithelial cell migration.  Am J Physiol Lung Cell Mol Physiol 2002; 282:L1108-L1116.

Kohyama T, Liu X, Zhu YK, Wen FQ, Wang H, Fang Q, Kobayashi T, Rennard SI.  Phosphodiesterase4 inhibitor cilomilast inhibits fibroblast-mediated collagen gel degradation induced by TNF-a neutrophil elastase.  Am J Respir Cell Molec Biol 2002; 27:1-8.

Rennard SI, Anderson W, ZuWallack R, Broughton J, Bailey W, Friedman M, Wisniewski M, Rickard K.  The use of a long-acting inhaled b2-adrenergic agonist, salmeterol xinafoate, in patients with COPD.  Am J Respir Crit Care 2001; 163:1087-1092.

Wen F-Q, Sköld CM, Liu X, Ertl RF, Zhu YK, Kohyama T, Wang H, Rennard SI.  Glucocorticoids and TGF-b1 synergize in augmenting fibroblast mediated contraction of collagen gels.  Inflammation 2001; 25:109-117

Zhu YK, Umino T, Liu XD, Wang HJ, Romberger DJ, Spurzem JR, Rennard SI.  Contraction of fibroblast containing collagen gels:  Initial collagen concentration regulates the degree of contraction and cell survival.  In Vitro Cell Dev Biol - Animal 2001; 37:10-16

Polosukhin VV, Manouilova LS, Romberger DJ, Matthews KI, Pirruccello SJ, West W, Daughton DM, Millatmal T, Umino T, Rennard SI. Ultrastructural heterogeneity of the alveolar macrophages from tobacco smokers with chronic bronchitis.  Ultrastructural Pathology 2001; 25:5-11.

Liu XD, Zhu YK, Umino T, Spurzem, Romberger DJ, Wang H, Reed E, Rennard SI.  Cigarette smoke inhibits osteogenic differentiation and proliferation of human osteoprogenitor in monolayer and three dimensional collagen gel culture.  J Lab Clin Med 2001; 137:208-219

Casale GP, Singhal M, Bhattacharya S, RamaNathan R, Roberts KP, Zhao J, Jankowiak R, Gross ML, Cavalieri EL, Small GJ, Rennard SI, Mumford JL, Shen M.  Detection and quantification of dupurinated benzo[a]pyrene-adducted DNA bases in the urine of cigarette smokers and women exposed to household coal smoke.  Chem Res in Toxicol  2001; 14:192-201.

Rennard SI, Anderson W, ZuWallack R, Broughton J, Bailey W, Friedman M, Wisniewski M, Rickard K.  The use of a long-acting inhaled b2-adrenergic agonist, salmeterol xinafoate, in patients with COPD.  Am J Respir Crit Care 2001; 163:1087-1092.

Liu XD, Umino T, Ertl R, Veys T, Sköld CM, Takigawa K, Romberger DJ, Spurzem JR, Zhu YK, Kohyama T, Wang H, Rennard SI.  Persistence of TGF-b1 induction of increased fibroblast contractility.  In Vitro 2001; 37:193-201.

Mio T, Liu X, Toews ML, Adachi A, Romberger DJ, Spurzem JR, Rennard SI.  Bradykinin augments fibroblast mediated contraction of released collagen gels.  Am J Phys 2001; 281:L164-L171.

Sköld CM, Ohkuni Y, Liu XD, Numerof R, Rennard SI.  Co-cultured human mast cells stimulate fibroblast-mediated contraction of collagen gels.  Inflammation 2001; 25:47-51.

Zhu YK, Liu XD, Sköld CM, Umino T, Wang HJ, Spurzem JR, Kohyama T, Ertl RF, Rennard SI.  Synergistic neutrophil elastase cytokine interaction leads to collagen degradation in three-dimensional collagen gel culture.  Am J Physiol Lung Cell Mol 2001; 281:L868-L878.

Zhu YK, Liu X-D, Sköld CM, Umino T, Wang H, Romberger DJ, Spurzem JR, Kohyama T, Wyatt T, Wen FQ, Rennard SI.  Cytokine inhibition of fibroblast induced gel contraction is mediated by PGE2 and NO acting through separate parallel pathways.  Am J Respir Cell Molec Biol 2001:25:245-253

Zhu YK, Liu XD, Ertl RF, Kohyama T, Wen FQ, Wang H, Spurzem JR, Romberger DJ, Rennard SI.  Retinoic acid attenuates cytokine-driven fibroblast degradation of extracellular matrix in three-dimensional culture. Am J Respir Cell Molec Biol 2001; 25:620-627.

Zhu YK, Sköld CM, Liu XD, Wang, H, Kohyama T, Wen FQ, Ertl RF, Rennard SI.  Fibroblasts and monocyte macrophages contract and degrade three-dimensional collagen gels in extended co-culture.  Respir Res 2001; 2:295-299.

Zhu YK, Liu XD, Sköld CM, Wang H, Kohyama T, Wen FQ, Ertl RF, Rennard SI.  Collaborative interactions between neutrophil elastase and metalloproteinases in extracellular matrix degradation in three-dimensional collagen gels.  Respir Res 2001; 2:300-305.

Kohyama T, Ertl RF, Valenti V, Spurzem J, Kawamoto M, Nakamura Y, Veys T, Allegra L, Romberger D, Rennard SI.  Prostaglandin E2 inhibits fibroblast chemotaxis.  Am J Phys 2001; 281:L1257-L1263.

Jamerson BD, Nides M, Jorenby DE, Donahue R, Garrett P, Johnston JA, Fiore MC, Rennard SI, Leischow SJ.  Late-term smoking despite initial failure:  An evaluation of bupropion sustained release, nicotine patch, combination therapy, and placebo.  Clinical Therapeutics 2001; 23:744-752.

Zhu Y, Liu XD, Wang HJ, Kohyama T, Wen FQ, Sköld CM, Rennard SI.  Interactions between monocytes and smooth muscle cells can lead to extracellular matrix degradation.  J Allergy Clin Immunol 2001; 108:989-996.

Liu XD, Zhu YK, Umino T, Spurzem, Romberger DJ, Wang H, Reed E, Rennard SI.  Cigarette smoke inhibits osteogenic differentiation and proliferation of human osteoprogenitor in monolayer and three dimensional collagen gel culture.  J Lab Clin Med 2001; 137:208-219.

Rennard SI, Schachter N, Streck M, Rickard K, Amit O.  Cilomilast for   COPD:  results of a six month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4.  Chest 2006; 129:56-66.

 

REVIEWS, BOOK CHAPTERS, EDITORIALS AND CORRESPONDENCE

Rennard SI.  Minimal clinically important difference, clinical perspective:  An opinion.  COPD;  J of Chronic Obstructive Pulmonary Disease 2005; 2:51-55

 Spurzem JR, Rennard SI.  Pathogenesis of COPD.  Semin Respir Crit Care Med, 2005; 26:142-153.

 

Rennard SI.  Minimal clinically important difference, clinical perspective:  an opinion.  COPD:  J COPD 2005; 2:51-55.

 

Rennard SI.  Combination therapy with bronchodilators.  In:  Therapeutic Strategies in COPD.  M Cazzola, B Celli, R Dahl, S Rennard (eds).  Clinical Publishing, Oxford, UK, 2005, pp. 137-149.

 Rennard SI.  Treatment of stable chronic obstructive pulmonary disease.  Lancet 2004; 364:791-80.

Rennard SI.  Introduction.  The symposium that never occurred:  pre-clinical and clinical development of sibenadet.  Resp Med 2003; 97:S1-2.

Rennard SI.  Pathogenesis of COPD.  Clinical Cornerstone 2003; 5:11-16.

Manda W, Rennard SI. Taking pharmacologic management of COPD into the future.  J Crit Illness 2003; 18:33-42.

Rennard SI.  Repair.  In:  Chronic Obstructive Pulmonary Disease.  PMA Calverley, W MacNee, NB Pride, SI Rennard (eds), Arnold, London, 2003, pp 139-150.

Rennard SI, Daughton DM.  Smoking cessation.  In:  Chronic Obstructive Pulmonary Disease.  PMA Calverley, W MacNee, NB Pride, SI Rennard (eds), Arnold, London, 2003, pp 327-340.

Rennard SI.  COPD: treatments benefit patients.  Lancet 2003; 361:44-445.

Piquette CA, Rennard SI.  Assessment of severity of acute exacerbation of chronic obstructive pulmonary disease. In:  Acute Exacerbation of Chronic Obstructive Pulmonary Disease, N. Siafakas (ed), Marcel Dekker, New York 2003; pp 203-227.

Toews ML, Ediger TL, Romberger DJ, Rennard SI.  Lysophosphatidic acid in airway function and disease.  Biochim Biophys Acta 2002; 1582:240-250.

Rennard SI.  New therapeutic drugs in the management of COPD.  Curr Opin Pulm Med 2002; 8:106-111.

Rennard SI.  Treatment for stable COPD. In:  Asthma and COPD, P. Barnes, J. Drazen, S. Rennard, N. Thomson (eds), Academic Press, Amsterdam, 2002, 713-726.

Rennard SI, Barnes PJ.  Pathogenesis of COPD. In:  Asthma and COPD, P. Barnes, J. Drazen, S. Rennard, N. Thomson (eds), Academic Press, Amsterdam, 2002, 361-379.

Spurzem JR, Rennard SI.  Epithelial cells.  In:  Asthma and COPD, P. Barnes, J. Drazen, S. Rennard, N. Thomson (eds), Academic Press, Amsterdam, 2002, 145-154.

Spurzem, J, Zhang J, Liu XD, Rennard SI, Romberger DJ.  Gene expression in an in vitro model of epithelial repair.  Chest 2002; 121:79S-80S.

Manda W, Rennard SI.  COPD in older adults, Part 1:  Prevalence, risk factors and diagnosis.  Geriatric Times 2002; 3:36-39.

Rennard SI.  Overview of causes of COPD.  Postgraduate Med 2002; 111:28-38.

Manda W, Rennard SI.  COPD in older adults, Part II:  Treatment strategies.  Geriatric Times 2002; 3:39-41.

Fabbri L, Rennard S, Leff A, O’Connor B.  Advances in the understanding and future therapy of COPD.  Clin Exp All Rev  2002; 2:129-136.

Daughton DM, Rennard SI.  Practice-based smoking cessation interventions. Eur Respir Rev 2002; 12:432-435.

Rennard SI, Farmer SG.  COPD in 2001.  A major challenge for medicine, the pharmaceutical industry and society.  Chest 2002; 151:113S-115S.

Rennard SI, Atwood J, Daughton DM.  Organisation of smoking cessation programmes:  the future.  Eur Respir Rev 2002; 12:436-438.

Rennard SI.  New understanding of the pathogenesis and mechanisms of COPD.  Postgraduate Medicine 2002; 111:28-30, 33-34, 37-38.

Johnson M, Rennard S.  Alternative mechanisms for long-acting b2-adrenergic agonists in COPD.  Chest 2001; 120:258-270.

Rennard SI.  Epithelial cells and fibroblasts.  In:  Chronic Obstructive Pulmonary Disease:  Pathogenesis to Treatment.  Novartis Foundation Symposium.  John Wiley & Sons, United Kingdom.  2001.  pp.104-119.

Lieberman P, Calhoun WJ, Panettieri RA, Peters SP, Rennard SI.  Asthma and irreversible lung disease:  Remodeling - fact or fiction?  Medical Crossfire 2001; 3:31-43.

Tran V, Rennard SI.  Lack of response to initial b-agonist therapy for acute COPD:  What to do?  J Crit Illness 2001; 16:114-117.

Rennard SI, Daughton DM.  Sevrage tabagique:  le rôle du bupropion.  La Lettre du Pneumologue 2001; 3:95-134.

Pauwels RA, Buist S, Calverley MA, Jenkins CR, Hurd SS on behalf of the GOLD Scientific Committee.  Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease.  Am J Respir Crit Care Med 2001; 163:1256-1276.

Rennard SI, Daughton DM.  Smoking cessation.  In: Chronic Obstructive Lung Disease, N.F. Voelkel, W. MacNee (eds), B.C. Decker, Inc., Hamilton, 2001, pp. 332-340.

Spurzem JR, Rennard SI.  The airway epithelium. In: Chronic Obstructive Lung Disease, N.F. Voelkel, W. MacNee (eds), B.C. Decker, Inc., Hamilton, 2001, pp. 21-40.

Back to Top

  • PREVIOUS GRADUATE STUDENTS/POST-DOCTORAL FELLOWS (present location):

Shinji Abe

 

Post

2000-2003

MD, PhD

The 4th Department of Internal Medicine, Nippon Medical School, Tokyo, Japan, Assistant Professor

Tetsu Kobayashi Post 2000-2005 MD, PhD Division of Pulmonary and Critical Care Medicine, The Third Department of Internal Medicine, Mie University Graduate School of Medicine, Mie, Japan
Lijun Mao Post 2004-2006 MD Department of Rheumatology, The Third Hospital of Peking University, Beijing, China

Stefano Carnevali

 

Post

1994-1995

MD

University degli Studi di Modena 3 Reggio Emilia, Sezione di Malattie, dell’Apparato Respiratorio, Policlinico, via del Pozzo, Modena, Italy

Mitsuyoshi Hashimoto

Post

2002-2004

MD, PhD

University of Nagoya, Najoya, Japan

Tadashi Mio

Post

1992-1995

MD, PhD

Kyoto University, Kyoto, Japan

Yuichi Adachi

Post

1992-1995

MD

Toyama University, Toyama, Japan

Kazu Aoshiba

Post

1994-1997

MD, PhD

Tokyo Women's Medical College, Tokyo, Japan

Kei Takigawa

Post

1995-1997

MD

Kagawa Medical School, Kagawa, Japan

Magnus Skold

Post

1996-1998

MD, PhD

Karolinska Institutet, Stockholm, Sweden

Qiuhong Fang

Post

2001-2004

MD, PhD

The First Hospital of Tsinghua University, Beijing, China

Mitsu Hashimoto

Post

Present

MD

Pulmonary Division, Department of Internal Medicine, Seoul Adventist Hospital, Seoul, Korea

Huijung Kim

 

Post

2000-2001

MD, PhD

Pulmonary Division, Department of Internal Medicine, Seoul Adventist Hospital, Seoul, Korea

Tadashi Kohyama

Post

1999-2001

MD

Department of Respiratory medicine, Graduate School of Medicine, University of Tokyo, Tokyo, Japan

Xiangde Liu

Post